

Medical Policy

Subject:	Uterine Transplantation	Publish Date:	04/07/2021
Document#:	TRANS.00037	Last Review Date:	02/11/2021
Status:	New		

Description/Scope

This document addresses uterine transplantation, which has been proposed as a treatment of uterine factor infertility. This procedure involves the transplantation of a healthy donor uterus obtained from living or recently deceased donor into an individual with a nonfunctioning or absent uterus. The scope of this document is limited to the transplant procedure only, and does not address other related infertility treatment or obstetric services.

Note: Please see the following for additional information:

- **CG-SURG-34 Diagnostic Infertility Surgery**

Position Statement

Investigational and Not Medically Necessary:

Uterine transplantation is considered investigational and not medically necessary for all uses, including but not limited to the treatment of uterine factor infertility due to nonfunctioning or absent uterus.

Rationale

Uterine transplantation has been proposed as an alternative to adoption and surrogacy for individuals with nonfunctioning or absent uterine factor infertility. The process starts with creating an embryo using in vitro fertilization (IVF) in which the women’s eggs are harvested, fertilized, and cryopreserved for transfer into the uterus following transplantation. A healthy uterus from a living or recently deceased donor is transplanted into the recipient. After approximately 6-12 months, if the transplanted organ has been deemed viable and functional a single embryo IVF implantation procedure is conducted. If the procedure leads to a

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Uterine Transplantation

successful pregnancy, the pregnancy is treated as high-risk and the child is delivered via Cesarean section at approximately 37 to 39 weeks. After one or two successful deliveries the transplanted uterus is removed via hysterectomy to avoid the continued need for immunosuppressive medication (Brännström, 2014).

Johannesson and colleagues (2015) reported primary outcomes from a prospective case series of human uterine transplantation from live donors (NCT01844362). The study enrolled 9 participants presenting with absolute UFI and viable uteri after undergoing live-donor uterine transplantation. The measured outcomes included menstruation, uterine artery blood flow, histology of cervical biopsy, and blood levels of tacrolimus. After the initial 6-month period, uterine grafts were removed in 2 participants, 1 related to persistent intrauterine infection and the other due to bilateral uterine vessel thrombosis. The authors reported initial 12-month outcomes on the 7 remaining participants, all of whom had normal menstrual patterns and uterine blood flow. A total of 9 rejection episodes (n=5) were reported; all cases were subclinical and asymptomatic, and detected by cervical biopsy. All resolved by temporary therapy with glucocorticoids.

The 2018 American Society of Reproductive Medicine (ASRM) position statement on uterus transplantation offers the following committee opinion:

- Uterus transplantation is an experimental procedure for the treatment of absolute uterus-factor infertility.
- Uterus transplantation should be performed within an IRB-approved research protocol.
- A uterus transplantation program requires a multidisciplinary team experienced with a technique prior to attempting transplantation in human subjects.
- The organ used during uterus transplantation can be for living or deceased donors; each approach has its own challenges and strengths.

Uterus transplantation is an experimental procedure that may allow women with absolute uterus-factor infertility to achieve a pregnancy.

There are recruiting and ongoing clinical trials studying uterine transplantation for treatment of uterine factor infertility due to congenital or nonfunctional uterus. However, to date, results from these studies have not been published. Data from prospective, long-term studies are needed to determine the safety and clinical utility of the procedure, including potential long-term effects of transplantation and anti-rejection medications on both the mother and the baby. [Other proposed uses which may further be explored in the](#)

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Uterine Transplantation

future are the “views of transgender women on their reproductive aspiration, motivations, and desire to undergo uterus transplant should it eventually be proven feasible” (Jones, 2021).

Background/Overview

According to Centers for Disease Control and Prevention, infertility affects nearly 6% of childbearing-aged women (15 to 44 years) in the United States. Nearly 1 per 5000 females is born with müllerian agenesis (also referred to as müllerian aplasia, Mayer-Rokitansky-Küster-Hauser syndrome, or vaginal agenesis), a rare condition caused by embryologic underdevelopment of the müllerian duct, with resultant agenesis or atresia of the vagina, uterus, or both.

The first uterus transplant was performed in Europe in 2014. As of 2020 there have been roughly 100 uterine transplants performed worldwide, including 30 in the United States under clinical trial. Several research studies into this procedure are underway.

Definitions

Institutional review board (IRB): An institutional review board is a group that has been formally designated to approve, monitor and review biomedical and behavioral research involving humans with the aim to protect the rights and welfare of the subjects. The Food and Drug Administration and the Office of Protection from Research Risks (part of the National Institutes of Health) set the guidelines and regulations governing human subject research and IRBs.

Uterine factor infertility: Condition where an individual woman cannot get pregnant because she either does not have a uterus or her uterus is no longer functioning correctly. This can be a result of a congenital condition or an acquired condition.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

When services are Investigational and Not Medically Necessary:
For the following procedure codes; or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

CPT
58999

Unlisted procedure, female genital system (nonobstetrical) [when specified as transplantation of uterus from a deceased or live donor, donor hysterectomy or other associated procedures]

Note: the following CPT codes are effective 07/01/2021

0664T

Donor hysterectomy (including cold preservation); open, from cadaver donor

0665T

Donor hysterectomy (including cold preservation); open, from living donor

0666T

Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor

0667T

Recipient uterus allograft transplantation from cadaver or living donor

0668T

Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary

0669T

Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each

0670T

Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each

ICD-10 Procedure

0UY90Z0

Transplantation of uterus, allogeneic, open approach

0UY90Z1

Transplantation of uterus, syngeneic, open approach

0UY90Z2

Transplantation of uterus, zooplastic, open approach

ICD-10 Diagnosis

N97.2

All diagnoses, including but not limited to the following:

Female infertility of uterine origin

References

This Medical Policy provides assistance in understanding Healthy Blue's standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue's Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Peer Reviewed Publications:

1. Brännström M, Johannesson L, Dahm-Kähler P, et al. First clinical uterus transplantation trial: a six-month report. Fertil Steril. 2014; 101(5):1228-1236.
2. Järvholm S, Enskog A, Hammarling C, et al, Uterus transplantation: joys and frustrations of becoming a ‘complete’ woman—a qualitative study regarding self-image in the 5-year period after transplantation, Human Reproduction, 2020; 35(8):1855-1863,
3. Johannesson L, Järvholm S. Uterus transplantation: current progress and future prospects. Int J Womens Health. 2016; 8:43-51.
4. Johannesson L, Kvarnström N, Mölne J, et al. Uterus transplantation trial: 1-year outcome. Fertil Steril. 2015; 103(1):199-204.
- 4-5. Jones BP, Rajamanoharan A, Vali S, et al. Perceptions and motivations for uterus transplant in transgender women. JAMA Network Open. 2021; 4(1):e2034561.
- 5-6. Testa G, Koon EC, Johannesson L, McKenna GJ, et al. Living Donor Uterus Transplantation: A Single Center’s Observations and Lessons Learned From Early Setbacks to Technical Success. Am J Transplant. 2017; 17(11):2901-2910.

Government Agency, Medical Society, and Other Authoritative Publications:

1. American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. 2015. Available at: <http://www.asrm.org/special-pages/search-results/?q=committee+opinion>. Accessed on November 19, 2020.
2. American Society for Reproductive Medicine (ASRM). American Society of Reproductive Medicine position statement on uterus transplantation: a committee opinion. Fertil Steril 2018; 110:605-610.

Websites for Additional Information

1. American Society for Reproductive Medicine. Available at: <http://www.asrm.org>. Accessed on November 19, 2020.
2. Centers for Disease Control and Prevention. Infertility FAQs. Last reviewed January 16, 2019. Available at: [https://www.cdc.gov/reproductivehealth/infertility/index.htm#:~:text=About%20%25%20of%20married%20women,marital%20status%20\(impaired%20fecundity\)](https://www.cdc.gov/reproductivehealth/infertility/index.htm#:~:text=About%20%25%20of%20married%20women,marital%20status%20(impaired%20fecundity)). Accessed on November 19, 2020.
3. United Network for Resource Sharing (UNOS). What organs can be transplanted? Available at: <https://unos.org/transplant/>. Accessed on November 19, 2020.

This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.


No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

Index

Uterine Transplantation

Document History

<u>Status</u>	<u>Date</u>	<u>Action</u>
New	02/11/2021	<u>Medical Policy & Technology Assessment Committee (MPTAC) review. Initial document development.</u>



This Medical Policy provides assistance in understanding Healthy Blue’s standard Medicaid benefit plan. When evaluating coverage for a specific member benefit, reference to federal and state law, as well as contractual requirements may be necessary, since these may differ from our standard benefit plan. In the event of a conflict with standard plan benefits, federal, state and/or contractual requirements will govern. Before using this policy, please check all federal, state and/or contractual requirements applicable to the specific benefit plan coverage. Healthy Blue reserves the right to modify its Policies and Guidelines as necessary and in accordance with legal and contractual requirements. This Medical Policy is provided for informational purposes. It does not constitute medical advice. Healthy Blue may also use tools and criteria developed by third parties, to assist us in administering health benefits. Healthy Blue’s Policies and Guidelines are intended to be used in accordance with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The member’s contract benefits in effect on the date that services are rendered must be used. Medical Policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.